FDA Could Shorten Food-Animal Drug Approval Timelines by 2 Years Through Risk-Based Residue Testing

FDA introduces a risk-based approach to residue analytical methods

The US Food and Drug Administration’s Center for Veterinary Medicine (CVM) has launched a voluntary pilot programme designed to streamline the process used to demonstrate that residue analytical methods for new food-animal drugs are practicable.

According to an FDA update on October 28, 2026, the agency estimates that the approach could reduce the overall human-food-safety residue evaluation by approximately two years in appropriate cases.

The programme targets a specific step in the development of new animal drugs intended for food-producing species. It does not remove the need to establish drug safety or eliminate applicable food-residue requirements.

Sources: dvm360 report, October 28, 2026 and the FDA’s pilot programme information.

Why residue analytical methods matter

When a veterinary drug is intended for animals that enter the human food supply, regulators need appropriate methods to detect and measure drug residues in relevant food products.

Depending on the species and product, these may include meat, milk, eggs and honey. The methods must be reliable and suitable for use by government laboratories.

Historically, demonstrating practicability could involve an interlaboratory trial in which a government laboratory confirms that it can run the analytical method consistently. The FDA has estimated that this stage alone can take about two years. Additional method changes and validation work may extend the timeline.

These requirements serve an important public-health purpose: the presence of an approved veterinary drug does not remove the need to ensure that residues can be monitored appropriately in food.

How the tiered pilot works

The pilot uses a risk-based framework called the Risk-Based Tiered Approach to Demonstrate Residue Analytical Method Practicability. It distinguishes between methods according to the agency’s confidence in their suitability.

The three tiers are described as:

• Tier 1 — negligible risk: Methods with characteristics that provide a high level of confidence may require fewer steps.

• Tier 2 — low risk: Methods with limited uncertainty are assessed under the corresponding tier requirements.

• Tier 3 — moderate risk: Methods with greater uncertainty are subject to a more demanding assessment.

The purpose is to avoid treating every method as if it presents the same level of technical or regulatory risk. The exact requirements depend on the method and its classification; sponsors should consult the current FDA documents rather than assume that a particular drug automatically qualifies for the least burdensome pathway.

The One Method Approach

A related component, the One Method Approach, combines validation criteria from VICH GL49 and FDA Guidance for Industry No. 3.

The approach is intended to allow sponsors to validate a single analytical method for both residue-depletion studies and the practicability submission where the requirements are met. This may avoid duplicate validation work and, in some cases, a second animal study.

The potential benefits are therefore broader than calendar time alone. Less duplicated work may also reduce development costs and unnecessary repetition of studies, while retaining the evidence needed for regulatory assessment.

Pilot participation and implementation

Participation is voluntary. The FDA has encouraged sponsors to contact CVM early in development to determine whether a method is suitable for the programme and to discuss classification.

According to the agency’s programme description reported by dvm360, the pilot is intended to continue until at least three new animal drug products complete the Tier 2 or Tier 3 process, or until the end of ADUFA VI, assuming the user-fee programme is reauthorised, whichever comes first.

The agency may revise programme documents as it gains experience. Sponsors should therefore confirm the current criteria and required documentation before changing development plans.

What this means for veterinary pharmaceutical companies

For manufacturers developing medicines for cattle, pigs, poultry and other food-producing species, residue evaluation is a critical part of regulatory planning.

The pilot could create opportunities to:

1. Improve development planning: Engage regulators early about analytical method requirements.

2. Reduce duplicated studies: Assess whether one appropriately validated method can support multiple required activities.

3. Reallocate resources: Potential time savings may allow teams to plan regulatory submissions and development milestones more efficiently.

4. Strengthen regulatory coordination: Analytical, toxicology, residue-depletion and regulatory teams should work together from an early stage.

The actual benefit will vary. A two-year estimate should not be interpreted as a guaranteed reduction in the total time needed to develop or approve every new food-animal drug.

Public-health safeguards remain central

The programme is intended to make a defined regulatory step more efficient, not to weaken residue protection. Reliable analytical methods remain necessary to support regulatory decisions concerning food safety.

Companies should continue to evaluate product-specific requirements, target species, residue depletion, analytical validation and applicable withdrawal periods as part of the development process.

Conclusion

The FDA’s risk-based residue-testing pilot could remove avoidable duplication from food-animal drug development. Its commercial value will depend on implementation, sponsor eligibility and the extent to which the proposed approach reduces delays without compromising analytical reliability or food safety.